CA2016659A1 - Compose stabilise contenant un facteur de croissance epidermique - Google Patents

Compose stabilise contenant un facteur de croissance epidermique

Info

Publication number: CA2016659A1
Authority: CA; Canada
Prior art keywords: growth factor; epidermal growth; compositions containing; stabilized compositions; containing epidermal
Prior art date: 1989-05-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA2016659A

Other languages

English (en)

Other versions

CA2016659C (fr

Inventor

John K. Cini

Amy L. Finkenaur

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ethicon Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-05-16

Filing date

1990-05-14

Publication date

1990-11-16

1990-05-14 Application filed by Individual filed Critical Individual

1990-11-16 Publication of CA2016659A1 publication Critical patent/CA2016659A1/fr

1996-12-10 Application granted granted Critical

1996-12-10 Publication of CA2016659C publication Critical patent/CA2016659C/fr

2010-05-14 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

102000009024 Epidermal Growth Factor Human genes 0.000 title abstract 3
101800003838 Epidermal growth factor Proteins 0.000 title abstract 3
229940116977 epidermal growth factor Drugs 0.000 title abstract 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title abstract 2
239000000203 mixture Substances 0.000 title 1
101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 abstract 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
150000001768 cations Chemical class 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
229940116978 human epidermal growth factor Drugs 0.000 abstract 1
239000002184 metal Substances 0.000 abstract 1
229910052751 metal Inorganic materials 0.000 abstract 1
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
-1 zinc Chemical class 0.000 abstract 1
229910052725 zinc Inorganic materials 0.000 abstract 1
239000011701 zinc Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Inorganic Compounds Of Heavy Metals (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

CA002016659A 1989-05-16 1990-05-14 Compose stabilise contenant un facteur de croissance epidermique Expired - Fee Related CA2016659C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/353,131 US5130298A (en)	1989-05-16	1989-05-16	Stabilized compositions containing epidermal growth factor
US353,131		1989-05-16

Publications (2)

Publication Number	Publication Date
CA2016659A1 true CA2016659A1 (fr)	1990-11-16
CA2016659C CA2016659C (fr)	1996-12-10

Family

ID=23387889

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002016659A Expired - Fee Related CA2016659C (fr)	1989-05-16	1990-05-14	Compose stabilise contenant un facteur de croissance epidermique

Country Status (11)

Country	Link
US (1)	US5130298A (fr)
EP (1)	EP0398619B1 (fr)
JP (1)	JP2763815B2 (fr)
KR (1)	KR900017580A (fr)
AU (1)	AU630952B2 (fr)
CA (1)	CA2016659C (fr)
DE (1)	DE69002795T2 (fr)
DK (1)	DK0398619T3 (fr)
ES (1)	ES2058799T3 (fr)
GR (1)	GR1000392B (fr)
PT (1)	PT94037B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326154B1 (en) *	1990-11-19	2001-12-04	Genentech, Inc.	Ligand-mediated immunofunctional hormone binding protein assay method
AU2489992A (en) *	1991-08-16	1993-03-16	Chiron Corporation	Muteins of epidermal growth factor exhibiting enhanced binding at low ph
US5618544A (en) *	1992-08-12	1997-04-08	Bays-Brown Dermatologics, Inc.	Method of decreasing cutaneous senescence
US5759548A (en) *	1993-11-30	1998-06-02	Lxr Biotechnology Inc.	Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
WO1995022560A1 (fr) *	1994-02-22	1995-08-24	The Syntex-Synergen Neuroscience Joint Venture	Formulations pharmaceutiques comprenant un facteur neurotrophique ciliaire
US6048545A (en) *	1994-06-24	2000-04-11	Biozone Laboratories, Inc.	Liposomal delivery by iontophoresis
CN1043732C (zh) *	1994-12-22	1999-06-23	大连医科大学	治疗口腔糜烂面的新型药膜
AU7678196A (en) *	1995-11-13	1997-06-05	Minimed, Inc.	Methods and compositions for the delivery of monomeric proteins
NZ335864A (en)	1996-11-06	2001-09-28	Univ California	Isolated tumor necrosis factor receptor releasing enzyme (TRRE), compositions comprising the enzyme and methods of the use in modulation of TNF levels
US20050191661A1 (en) *	1996-11-06	2005-09-01	Tetsuya Gatanaga	Treatment of inflammatory disease by cleaving TNF receptors
US6593456B1 (en) *	1996-11-06	2003-07-15	The Regents Of The University Of California	Tumor necrosis factor receptor releasing enzyme
US6495532B1 (en) *	1997-03-19	2002-12-17	Sky High, Llc	Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US6949528B1 (en)	1998-03-18	2005-09-27	Goddard John G	Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
US7033615B2 (en) *	1999-07-09	2006-04-25	Cancer2 Inc.	Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues
US6541447B1 (en)	1999-09-01	2003-04-01	B & M Healthcare Technologies, Inc.	Wound healing composition and method for use thereof
GB0001621D0 (en)	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
US20060063738A1 (en) *	2000-02-28	2006-03-23	Sky High, Llc	Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US20070087965A1 (en) *	2005-10-03	2007-04-19	Neirinckx Rudi D	Treatment of psoriasis through down-regulation of the egf-receptor with topically applied egf
US7015199B1 (en) *	2000-06-02	2006-03-21	Neirinckx Rudi D	Treatment of psoriasis through down-regulation of the EGF-receptor with topically-applied EGF
DE60139874D1 (de) *	2000-07-28	2009-10-22	Christopher J Murphy	Medium für transplantat
CU23043A1 (es) *	2001-12-20	2005-05-20	Ct Ingenieria Genetica Biotech	Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
US7517528B2 (en)	2002-03-12	2009-04-14	Bio-Click Technologies, Ltd.	Method and composition for treating skin wounds with epidermal growth factor
SE0202719D0 (sv) *	2002-09-13	2002-09-13	Pharmacia Ab	Process for mfg crystals of growth hormone
US20050214382A1 (en) *	2004-03-29	2005-09-29	Erning Xia	Zinc preservative composition and method of use
US20070207209A1 (en) *	2004-08-27	2007-09-06	Murphy Christopher J	Trophic factor combinations for nervous system treatment
US8481049B2 (en)	2005-05-27	2013-07-09	Bharat Biotech International Limited	Methods for treating a wound using epidermal growth factor formulation
CU23411B6 (es) *	2005-12-29	2009-09-08	Ct Ingenieria Genetica Biotech	Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
CU23388B6 (es) *	2006-01-31	2009-07-16	Ct Ingenieria Genetica Biotech	Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
TWI394564B (zh) *	2006-09-21	2013-05-01	Alcon Res Ltd	自行保存型水性藥學組成物
AU2007304996B2 (en) *	2006-09-28	2013-03-21	Novartis Ag	Self-preserved aqueous pharmaceutical compositions
CU23526B6 (es) *	2006-10-03	2010-05-19	Ct Ingenieria Genetica Biotech	Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
KR100784134B1 (ko) *	2006-10-09	2007-12-12	주식회사 대웅	상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
CN101959500A (zh) *	2008-03-17	2011-01-26	爱尔康研究有限公司	包含硼酸类化合物-多元醇络合物的水性药物组合物
JP5303322B2 (ja) *	2009-03-13	2013-10-02	ピアス株式会社	皮膚外用組成物
TWI489997B (zh) *	2009-06-19	2015-07-01	Alcon Res Ltd	含有硼酸－多元醇錯合物之水性藥學組成物
SG181969A1 (en) *	2010-01-06	2012-08-30	Orf Liftaekni Hf	Method of use of stabilized plant-derived growth factor in skin care
HRP20192207T1 (hr)	2010-08-11	2020-02-21	Ironwood Pharmaceuticals, Inc.	Stabilne formulacije linaklotida
JP5798356B2 (ja) *	2011-04-06	2015-10-21	一般財団法人化学及血清療法研究所	新規インフルエンザワクチン安定化剤
PE20151673A1 (es)	2013-03-15	2015-11-27	Genentech Inc	POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
US9283172B2 (en)	2013-12-13	2016-03-15	Growgene Biotech Inc.	Use of stem cell conditioned medium to induce ZO-1 proteins expression for skin regeneration, repair and firming
KR101868966B1 (ko) *	2016-05-12	2018-06-19	주식회사 엔씨엘바이오	열 안정성을 증진시킨 사람 상피세포 성장인자의 조성물
SG11202006259SA (en)	2018-01-26	2020-08-28	Genentech Inc	Il-22 fc fusion proteins and methods of use
LT3743088T (lt)	2018-01-26	2022-12-27	F. Hoffmann-La Roche Ag	Il-22 fc kompozicijos ir jų naudojimo būdai
JP2021514354A (ja)	2018-02-21	2021-06-10	ジェネンテック，インコーポレイテッド	ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL38546A0 (en) *	1971-01-20	1972-03-28	Richter Gedeon Vegyeszet	A process for the preparation of new complexes of biologically active peptides,polypeptides,proteins or derivatives or salts thereof having prolonged and/or increased activity
US3887704A (en) *	1974-03-12	1975-06-03	Joseph Lichtenstein	Aqueous zinc solutions for physiological use
FI78616C (fi) *	1982-02-05	1989-09-11	Novo Industri As	Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
DK113585D0 (da) *	1985-03-12	1985-03-12	Novo Industri As	Nye peptider
HU194280B (en) *	1985-10-22	1988-01-28	Richter Gedeon Vegyeszet	Process for producing new gonadoliberin analogues of high effectivity and pharmaceutical compositions containing them
US4816568A (en) *	1986-05-16	1989-03-28	International Minerals & Chemical Corp.	Stabilization of growth hormones
AU8175387A (en) *	1986-10-20	1988-05-06	Novo Industri A/S	Protamine zinc insulin preparations
US4717717A (en) *	1986-11-05	1988-01-05	Ethicon, Inc.	Stabilized compositions containing epidermal growth factor
US4764592A (en) *	1987-04-23	1988-08-16	Eli Lilly And Company	Crystalline human proinsulin and process for its production
DE3731255A1 (de) *	1987-09-17	1989-04-06	Boehringer Ingelheim Int	Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
US5272063A (en) *	1988-11-22	1993-12-21	Syntex (U.S.A.) Inc.	Process of making human nerve growth factor

1989
- 1989-05-16 US US07/353,131 patent/US5130298A/en not_active Expired - Lifetime
1990
- 1990-05-07 GR GR900100334A patent/GR1000392B/el not_active IP Right Cessation
- 1990-05-11 AU AU54968/90A patent/AU630952B2/en not_active Ceased
- 1990-05-14 KR KR1019900006828A patent/KR900017580A/ko not_active Withdrawn
- 1990-05-14 CA CA002016659A patent/CA2016659C/fr not_active Expired - Fee Related
- 1990-05-15 ES ES90305185T patent/ES2058799T3/es not_active Expired - Lifetime
- 1990-05-15 PT PT94037A patent/PT94037B/pt active IP Right Grant
- 1990-05-15 EP EP90305185A patent/EP0398619B1/fr not_active Expired - Lifetime
- 1990-05-15 DE DE90305185T patent/DE69002795T2/de not_active Expired - Lifetime
- 1990-05-15 DK DK90305185.2T patent/DK0398619T3/da active
- 1990-05-15 JP JP2123208A patent/JP2763815B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
GR1000392B (el)	1992-06-30
ES2058799T3 (es)	1994-11-01
GR900100334A (en)	1991-10-10
US5130298A (en)	1992-07-14
PT94037A (pt)	1991-01-08
EP0398619B1 (fr)	1993-08-18
DE69002795D1 (de)	1993-09-23
JP2763815B2 (ja)	1998-06-11
PT94037B (pt)	1996-11-29
JPH0334992A (ja)	1991-02-14
EP0398619A3 (fr)	1991-04-03
AU630952B2 (en)	1992-11-12
EP0398619A2 (fr)	1990-11-22
KR900017580A (ko)	1990-12-19
AU5496890A (en)	1990-11-22
DK0398619T3 (da)	1993-10-04
DE69002795T2 (de)	1994-01-13
CA2016659C (fr)	1996-12-10

Legal Events

Date	Code	Title	Description
1991-07-17	EEER	Examination request
2009-05-14	MKLA	Lapsed

Publication	Publication Date	Title
EP0398619A3 (fr)	1991-04-03	Compositions stabilisées contenant le facteur de croissance épidermique
CA2182582A1 (fr)	1995-08-24	Compositions contenant du nebivolol micronise
HU9303035D0 (en)	1994-02-28	N-amino-alkyl-carbonyloxy-alkyl-pyrrol derivatives and insecticidal acaricidal and molluscicidal compositions containing the compounds as active ingredients
AU6225490A (en)	1991-03-14	Photoprotection compositions having reduced dermal irritation
OA09772A (en)	1993-11-30	"mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
WO1997012583A3 (fr)	1997-06-05	Compositions stables contenant du n-propargyl-1-aminoindane
AU5115393A (en)	1994-04-26	Novel derivatives of taxol analogues, preparation thereof and compositions containing them
CA2152615A1 (fr)	1994-07-07	Compositions pharmaceutiques a base d'atovaquone
IL107870A0 (en)	1994-04-12	Pharmaceutical compositions having antidepressant activity comprising pramipexol
AU6168190A (en)	1991-04-03	Methylenediphosphonic acid compound and anti-inflammatory containing the same as active ingredient
GB8902929D0 (en)	1989-03-30	Insecticide treatment & compositions therefor
HUP9900365A3 (en)	1999-11-29	N-aryl-1,2,4-triazolin-5-on derivatives, preparation and use thereof, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients
TW334434B (en)	1998-06-21	Novel quinazoline compound and anti-tumor agent
IL124431A0 (en)	1998-12-06	Sulfur containing dl-tert-butylphenol compounds useful as anti-inflammatory agents
HU900865D0 (en)	1990-05-28	Fungicidal compositions comprising 2-anilino-cyanopyridines and process for preparation of the active ingredient
HUT54358A (en)	1991-02-28	Process for producing substituted 1,3,5-triazinetrione derivatives and medical compositions comprising such compounds as active ingredient
IL106288A0 (en)	1993-11-15	Skin regenerating cosmetic compositions
GR3005282T3 (fr)	1993-05-24
AU3549593A (en)	1993-10-07	Cosmetic compositions
CA2075926A1 (fr)	1991-08-16	Esters d'acides amines et d'hydroquinone, methodes d'obtention et compositions phramaceutiques ou cosmetiques qui en contiennent
HUT52763A (en)	1990-08-28	Herbicide and growth-controlling compositions containing sulfonyl-urea derivatives as active components and process for producing the active components
HUT46364A (en)	1988-10-28	Process for producing 1,12-dihydroxy-1,6,12,13-tetraaza-dicyclodocosane-2,5,13,16-tetron and pharmaceutical compositions comprising this compound as active ingredient
IL110780A0 (en)	1994-11-11	Pharmaceutical compositions containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol for the treatment of the common cold
AU669783B2 (en)	1996-06-20	Dermatologic preparation composition containing prostacyclinas active ingredient
EP0348664A3 (fr)	1990-11-07	Compositions pharmaceutiques contenant des monoacétoacétines pour le traitement des tumeurs